Our Take
Labcorp is adding supply to an existing market category, not creating a new one; the real story is whether Geneoscopy's economics or accuracy outpace Cologuard enough to shift ordering patterns.
Why it matters
Colorectal cancer screening adoption remains below clinical targets in the U.S., and competition in at-home testing may lower barriers to compliance. Labcorp's scale and distribution network could make screening more accessible, but only if the test performs as well as or better than the established alternative.
Do this week
Pathologists and primary care leaders: compare Geneoscopy's sensitivity, specificity, and turnaround time against Cologuard published data before adding it to your screening protocol.
Labcorp enters the at-home colorectal cancer screening market
Labcorp is bringing the Geneoscopy test to market nationwide, directly competing with Exact Sciences' Cologuard in the non-invasive colorectal cancer screening segment. The move marks Labcorp's entry into a category where Cologuard has held substantial share among patients and clinicians seeking alternatives to colonoscopy.
The timing positions Labcorp to leverage its existing laboratory footprint and patient relationships, a distribution advantage Exact Sciences built over years. Both tests target the same screening population: adults aged 45 and older at average or elevated risk who prefer a home-based sample over endoscopy.
Supply alone doesn't shift the market
Cologuard's dominance in at-home colorectal cancer screening rests on clinical validation and years of insurance reimbursement negotiation, not on Labcorp's inability to offer a comparable test. Labcorp's advantage is operational: it can reach providers through existing relationships and potentially offer pricing or turnaround-time benefits that create friction for switching from Cologuard.
The real test is whether Geneoscopy's clinical performance justifies that friction. If sensitivity and specificity match published Cologuard data, the choice becomes cost and convenience. If Geneoscopy underperforms, ordering clinicians have no reason to change. Labcorp's scale is a necessary condition, not a sufficient one.
Screening adoption rates for colorectal cancer remain below 70% in the U.S. population, well short of clinical targets. Expanded options and competition may lower costs or reduce wait times, which could drive adoption, but only if the new entrant delivers equivalent clinical confidence to patients and their providers.
Audit your colorectal screening protocol
If you currently recommend Cologuard, request Geneoscopy's published sensitivity and specificity data, as well as insurance panel status and typical turnaround time. Do not add Geneoscopy to your protocol based on availability alone; the clinical case must match or exceed Cologuard's track record. Check whether your EHR integration and patient communication workflows are optimized for whichever test you recommend—switching later costs effort and patient confusion.
For practices considering a change, negotiate reimbursement rates and out-of-pocket costs directly with Labcorp rather than assuming pricing parity with Cologuard. Labcorp's incentive to win share may include temporary discounts; lock favorable terms before the market stabilizes.